Biopharma Daily Stock Updates - 04/28/21

$XBI $140 +1%

Covid Updates

$AMPE +3% Phase 1 data for AP-014 for respiratory distress in patients as a result of COVID-19. source

Pipeline Updates

$XNCR +2% Doses first patient in ph 1 study of XmAb564 for autoimmune diseases in healthy volunteers. source

$GRTX +32% Updated ph 1/2 pilot study data supports ph 2 initiation planned for H1 2021. source

$ADVM -48% Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony found in ph 2 INFINITY study, company unmasked data and is analyzing. source

$NKTX -1% IND cleared for NKX019 for R/R B cell malignancies. source

$AKTX -2% Nomacopan granted Fast Track Designation by FDA for BP. source

$GTHX -1% Initiation of ph 3 pivotal study of Cosela for mTNBC. source

$ADMA +8% FDA approved increased manufacturing processes for BIVIGAM. source

$TRIL -7% Provides data for ph 1 TTI-662 and TTI-621, and update for phase 1b/2 programs in hematologic and solid tumor indications, first patient dosed in ph 1b/2 of TTI-662 combo for R/R MM. source

$CALT +4% FDA accepted NDA and granted priority review for Nefecon for the treatment of IgA nephropathy (IgAN). PDUFA target date has been set for 9/15/21. source

$PLX -35% CRL received base on FDA unable to conduct facility inspection in Israel due to travel restrictions. Company will request Type-A meeting with FDA. source

Finance Updates

$NYMX -15% $8M private placement at $2.18/share. source